
Dr. Antonio Calles π«π
@tony_calles
Medical Oncology π₯ Hospital General Universitario Gregorio MaraΓ±Γ³n & @RuberInter βͺ@myESMO Faculty π« βͺ#endlungcancer #lcsm
ID: 2155543177
http://www.linkedin.com/in/antonio-calles-001 25-10-2013 19:57:31
24,24K Tweet
11,11K Followers
4,4K Following



These results will confirm the restriction on nivolumab approval to PD-L1+ve patients in Europe by EU Medicines Agency previously based on EFS data. #ASCO25 #LCSM



Dr. Luis Paz-Ares at #ASCO25 with phase III IMforte trial. Adding maintenance lurbinectidin to first-line maintenance atezolizumab in ES #SCLC improves both PFS & OS, meeting primary endpoints. PFS HR 0.54 and OS HR 0.73 with use of lurbinectedin. Value in avoiding attrition.






Here are the top trials from day 4 of ASCO 2025. Follow us and get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #ASCO2025 #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare | Paolo Tarantino | Dr Sarah Sammons | Stephen V Liu, MD | Dr. Antonio Calles π«π |


π€ The lurbinectedin + immunotherapy team. The PIs of IMforte, LUPER, and 2SMALL together. #ASCO25 #LCSM SmallCellSMASHERS


βοΈ A hombros de gigantes. Tiempo de despedidas y de legados. Reconocimiento institucional y humano al Dr. Miguel Cuervo, un MΓDICO con mayΓΊsculas. π₯ #MaraΓ±on Sarcomas Hospital Gregorio MaraΓ±Γ³n #CSUR


